Most-cited articles · 2024
The 10 most-cited articles in American Journal of Psychiatry, 2024
Ranked by OpenAlex citation count on 29 October 2026, out of 126 eligible articles American Journal of Psychiatry published in 2024. Ranks are frozen; this page will not change. Number one, with 140 citations: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice.
- Cohort
- 126 articles
- Listed
- Top 10 (7.9%)
- Open access
- 5 of 10
- Snapshot
- 2026-10-29
The most-cited articles published in American Journal of Psychiatry in 2024 cluster around several themes. Reviews of clinical practice and therapeutics feature prominently, including the top paper, "Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice" by Matthias Brand, Stephanie Antons, Beáta Bőthe and colleagues, with 140 citations. Other highly cited reviews address antipsychotic drugs, psychotropic drug-related weight gain, irritability in youths, and the neurobiology and treatment of posttraumatic stress disorder. A second theme is substance use and overdose, covering widening racial inequalities in drug overdose and predictors of substance use initiation by early adolescence. Treatment studies, including a meta-analysis of cognitive remediation in schizophrenia and a randomized comparison of rTMS in antidepressant nonresponders, also rank highly.
For readers, the list offers a snapshot of the work that drew the most citation attention in the journal during 2024. It shows which topics and article types were most frequently referenced, spanning reviews, meta-analyses, randomized trials, and national trend studies. The ranking reflects citation counts from OpenAlex among 126 eligible articles and does not by itself indicate quality or clinical importance.
Introduction written from the titles and abstracts on this list. Every figure below is the source.
Ask about these papers
Grounded in this list only, with sources.
- 1top 0.8%
Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice
Matthias Brand, Stephanie Antons, Beáta Bőthe, Zsolt Demetrovics, Naomi Anne Fineberg and 7 more
140 citationsOpen accessdoi:10.1176/appi.ajp.20240092OpenAlex
Show abstractHide abstract
Gambling disorder is the only behavioral addiction recognized as a clinical disorder in DSM-5, and Internet gaming disorder is included as a condition requiring further research. ICD-11 categorizes gambling and gaming disorders as disorders due to addictive behaviors. Additional behavioral addictions may include compulsive sexual behavior disorder, compulsive buying-shopping disorder, and problematic use of social media. This narrative review summarizes the current state of knowledge regarding these five (potential) disorders due to addictive behaviors. All five (potential) disorders are clinically relevant and prevalent. Behavioral addictions frequently co-occur with other mental and behavioral problems, such as depression, anxiety, and attention deficit hyperactivity disorder. Validated diagnostic instruments exist, with empirical support varying across conditions. No medications have approved indications from regulatory bodies for behavioral addictions, and cognitive-behavioral therapy has the most empirical support for efficacious treatment. Given that behavioral addictions are…
- 2top 1.6%
Irritability in Youths: A Critical Integrative Review
Ellen Leibenluft, Laura E. Allen, Robert R. Althoff, Melissa A. Brotman, Jeffrey D. Burke and 21 more
132 citationsOpen accessdoi:10.1176/appi.ajp.20230256OpenAlex
Show abstractHide abstract
Irritability, defined as proneness to anger that may impair an individual's functioning, is common in youths. There has been a recent upsurge in relevant research. The authors combine systematic and narrative review approaches to integrate the latest clinical and translational findings and provide suggestions for addressing research gaps. Clinicians and researchers should assess irritability routinely, and specific assessment tools are now available. Informant effects are prominent, are stable, and vary by age and gender. The prevalence of irritability is particularly high among individuals with attention deficit hyperactivity disorder, autism spectrum disorder, and mood and anxiety disorders. Irritability is associated with impairment and suicidality risk independent of co-occurring diagnoses. Developmental trajectories of irritability (which may begin early in life) have been identified and are differentially associated with clinical outcomes. Youth irritability is associated with increased risk of anxiety, depression, behavioral problems, and suicidality later in life.…
- 3top 2.4%
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Stefan Leucht, Josef Priller, John M. Davis
116 citationsdoi:10.1176/appi.ajp.20240738OpenAlex
Show abstractHide abstract
The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN). Antipsychotic drugs are not specific for treating schizophrenia. They reduce psychosis regardless of the underlying diagnosis, and they go beyond nonspecific sedation. All currently available antipsychotic drugs are dopamine blockers or dopamine partial agonists. In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment. A major unresolved problem is the implausible increase in placebo response in antipsychotic drug trials over the decades. Differences in side effects, which can be objectively measured, such as weight gain, are less equivocal…
- 4top 3.2%
Psychotropic Drug–Related Weight Gain and Its Treatment
Roger S. McIntyre, Angela T.H. Kwan, Joshua Daniel Rosenblat, Kayla M. Teopiz, Rodrigo Barbachan Mansur
116 citationsdoi:10.1176/appi.ajp.20230922OpenAlex
Show abstractHide abstract
Psychotropic drug-related weight gain (PDWG) is a common occurrence and is highly associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs. Moreover, PDWG intersects with the elevated risk for obesity and associated morbidity that has been amply reported in the psychiatric population. Evidence indicates that differential liability for PDWG exists for antipsychotics, antidepressants, and anticonvulsants. During the past two decades, agents within these classes have become available with significantly lower or no liability for PDWG and as such should be prioritized. Although lithium is associated with weight gain, the overall extent of weight gain is significantly lower than previously estimated. The benefit of lifestyle and behavioral modification for obesity and/or PDWG in psychiatric populations is established, with effectiveness similar to that in the general population. Metformin is the most studied pharmacological treatment in the prevention and treatment of PDWG, and promising data are emerging for glucagon-like peptide-1 (GLP-1) receptor…
- 5top 4%
Understanding and Addressing Widening Racial Inequalities in Drug Overdose
Joseph R. Friedman, Max Jordan Nguemeni Tiako, Helena Hansen
84 citationsOpen accessdoi:10.1176/appi.ajp.20230917OpenAlex
Show abstractHide abstract
The fourth wave of the United States overdose crisis-driven by the polysubstance use of fentanyl with stimulants and other synthetic substances-has driven sharply escalating racial/ethnic inequalities in drug overdose death rates. Here the authors present a detailed portrait of the latest overdose trends and synthesize the literature to describe where, how, and why these inequalities are worsening. By 2022 overdose deaths among Native and Black Americans rose to 1.8 and 1.4 times the rate seen among White Americans, respectively. This reflects that Black and Native Americans have been disproportionately affected by fentanyl and the combination of fentanyl and stimulants at the national level and in virtually every state. The highest overdose deaths rates are currently seen among Black Americans 55-64 years of age as well as younger cohorts of Native Americans 25-44 years of age. In 2022-the latest year of data available-deaths among White Americans decreased relative to 2021, whereas rates among all other groups assessed continued to rise. Moving forward, Fundamental Cause Theory…
- 6top 4.8%
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Antonio Vita, Stefano Barlati, Anna Ceraso, Gabriele Nibbio, Francesca Durante and 3 more
70 citationsdoi:10.1176/appi.ajp.20230396OpenAlex
Show abstractHide abstract
OBJECTIVE: Cognitive remediation provides substantial improvements in cognitive performance and real-world functioning for people living with schizophrenia, but the durability of these benefits needs to be reassessed and better defined. The aims of this study were to provide a comprehensive assessment of the durability of the benefits of cognitive remediation for cognition and functioning in people living with schizophrenia and evaluating potential moderators of effects. METHODS: A systematic search was conducted in PubMed, Scopus, and PsycINFO, and reference lists of included articles and Google Scholar were inspected. Eligible studies were randomized clinical trials of cognitive remediation in patients diagnosed with schizophrenia spectrum disorders in which follow-up assessments were included. Screening and data extraction were performed by at least two independent reviewers. Cohen's d was used to measure outcomes. Primary outcomes were changes in cognition and functioning from baseline to conclusion of follow-up. Moderators of the durability of effects were assessed. RESULTS: Of…
- 7top 5.6%
Predictors of Substance Use Initiation by Early Adolescence
ReJoyce Green, Bethany Jacobs Wolf, Andrew Chen, Anna E. Kirkland, Pamela Lynn Ferguson and 6 more
66 citationsOpen accessdoi:10.1176/appi.ajp.20230882OpenAlex
Show abstractHide abstract
OBJECTIVE: Substance use initiation during early adolescence is associated with later development of substance use and mental health disorders. This study used various domains to predict substance use initiation, defined as trying any nonprescribed substance (e.g., alcohol, tobacco, cannabis), by age 12, using a large longitudinal data set. METHODS: Substance-naive youths from the Adolescent Brain Cognitive Development Study (ages 9-10; N=6,829) were followed for 3 years. A total of 420 variables were examined as predictors of substance use initiation, using a penalized logistic regression with elastic net; domains spanned demographic characteristics, self and peer involvement with substance use, parenting behaviors, mental and physical health, culture and environment, hormones, neurocognitive functioning, and structural neuroimaging. RESULTS: =0.66). Sociodemographic factors were the most robust predictors, followed by cultural and environmental factors, physical health factors, and parenting behaviors. The top predictor was a religious preference of Mormon (coefficient=-0.87),…
- 8top 6.4%
rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches
Iris Dalhuisen, Iris van Oostrom, Jan Spijker, Ben F. M. Wijnen, Eric R. van Exel and 5 more
65 citationsOpen accessdoi:10.1176/appi.ajp.20230556OpenAlex
Show abstractHide abstract
OBJECTIVE: Although repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for depression, little is known about the comparative effectiveness of rTMS and other treatment options, such as antidepressants. In this multicenter randomized controlled trial, rTMS was compared with the next pharmacological treatment step in patients with treatment-resistant depression. METHODS: Patients with unipolar nonpsychotic depression (N=89) with an inadequate response to at least two treatment trials were randomized to treatment with rTMS or to a switch of antidepressants, both in combination with psychotherapy. Treatment duration was 8 weeks and consisted of either 25 high-frequency rTMS sessions to the left dorsolateral prefrontal cortex or a switch of antidepressant medication following the Dutch treatment algorithm. The primary outcome was change in depression severity based on the Hamilton Depression Rating Scale (HAM-D). Secondary outcomes were response and remission rates as well as change in symptom dimensions (anhedonia, anxiety, sleep, rumination, and cognitive…
- 9top 7.2%
Neurobiology and Treatment of Posttraumatic Stress Disorder
Arieh Y. Shalev, Dayeon Cho, Charles R. Marmar
60 citationsdoi:10.1176/appi.ajp.20240536OpenAlex
Show abstractHide abstract
The recent worldwide surge of warfare and hostilities exposes increasingly large numbers of individuals to traumatic events, placing them at risk of developing posttraumatic stress disorder (PTSD) and challenging both clinicians and service delivery systems. This overview summarizes and updates the core knowledge of the genetic, molecular, and neural circuit features of the neurobiology of PTSD and advances in evidence-based psychotherapy, pharmacotherapy, neuromodulation, and digital treatments. While the complexity of the neurobiology and the biological and clinical heterogeneity of PTSD have challenged clinicians and researchers, there is an emerging consensus concerning the underlying mechanisms and approaches to diagnosis, treatment, and prevention of PTSD. This update addresses PTSD diagnosis, prevalence, course, risk factors, neurobiological mechanisms, current standard of care, and innovations in next-generation treatment and prevention strategies. It provides a comprehensive summary and concludes with areas of research for integrating advances in the neurobiology of the…
- 10top 8%
National Trends in Emergency Department Visits for Suicide Attempts and Intentional Self-Harm
Tanner J. Bommersbach, Mark Olfson, Taeho Greg Rhee
60 citationsdoi:10.1176/appi.ajp.20230397OpenAlex
Show abstractHide abstract
OBJECTIVE: This study estimated national annual trends and characteristics of emergency department visits for suicide attempts and intentional self-harm in the United States from 2011 to 2020. METHODS: Data were from the National Hospital Ambulatory Medical Care Survey, an annual cross-sectional national sample survey of emergency departments. Visits for suicide attempts and intentional self-harm were identified using discharge diagnosis codes (ICD-9-CM for 2011-2015; ICD-10-CM for 2016-2020) or reason-for-visit codes. The annual proportion of emergency department visits for suicide attempts and intentional self-harm was estimated. RESULTS: The weighted number of emergency department visits for suicide attempts and intentional self-harm increased from 1.43 million, or 0.6% of total emergency department visits, in 2011-2012 to 5.37 million, or 2.1% of total emergency department visits in 2019-2020 (average annual percent change, 19.5%, 95% CI=16.9, 22.2). Visits per capita increased from 261 to 871 visits per 100,000 persons (average annual percent change, 18.8%, 95% CI=17.6, 20.0).…
How to read this list
The cohort is every article, review and book chapter OpenAlex attributes to American Journal of Psychiatry with publication year 2024, excluding retracted works and paratext such as editorials and errata. The top 10 by citation count are listed; the percentile is the rank divided by the cohort size. 10 of the 10 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.
Other journals, same idea
Work with these 10 papers in Kahubi
- The papers land in your library with their DOIs
- Ask anything across all of them, with citations
- Draft a literature review from the same sources
Free plan, no card. Your files stay private unless you share them.
Reading several of these?
Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.